Gut microbiome metabolites linked to Alzheimer's risk

New research suggests a significant link between the gut microbiome and cognitive decline, specifically regarding Alzheimer's disease. Scientists have identified imidazole propionate (ImP), a metabolite produced by gut bacteria during the breakdown of histidine, as a key factor in this process.

Studies involving over 1,100 cognitively healthy adults found that higher levels of ImP in the blood correlate with lower cognitive test scores and increased levels of Alzheimer's-related biomarkers, such as amyloid beta and tau proteins. Research indicates that ImP may weaken the blood-brain barrier, allowing the metabolite to reach brain tissue and exacerbate neurodegeneration. Genetic analysis further suggests that certain genetic variants increase ImP levels, which in turn raises the risk of Alzheimer's.

Additional studies on mice indicate that changes in the gut microbiome can disrupt communication between the gut and the brain via the vagus nerve. This disruption can lead to inflammation and reduced activity in the hippocampus, the brain region responsible for memory. Researchers observed that age-related changes in the microbiome, including the presence of the bacterium Parabacteroides goldsteinii, contribute to these cognitive impairments, though some effects appeared reversible through interventions.